These findings underscore the need for studying further non-mobilised PB CD34+ cells for haematopoietic stem cell therapy (HSCT) regimes, since they may be more beneficial in some autoimmune disease treatments, including SLE, as reported recently34. This evidence concerns the gene CD34 and systemic lupus erythematosus.